Indian co gets licence to produce flu vaccine

NEW YORK - A US firm Tuesday announced that it has granted an Indian biopharmaceutical company a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialisation of the vaccine in India, according to media reports.
Under the terms of the agreement between New Jersey-based VaxInnate Corporation and India Biological E Limited, the vaccine will enter clinical development in India early this year and could become available for emergency use in India after completion of clinical trials. As with all new vaccines, the Indian Government must approve the vaccine based upon clinical evaluation before it can be used. Financial terms of the agreement include initial fees, milestone payments and royalties on sales.
The agreement also permits Biological E to sell excess vaccine to other South Asian countries, including Pakistan, Bangladesh, Bhutan, the Maldives, Nepal and Sri Lanka.